And more importantly, L18I can cause the decrease of BTK protein level in mutant diffuse large B-cell lymphoma (DLBCL) tumor, thereby effectively inhibiting the growth of the tumor in vivo and overcoming the tumor resistance to Ibrutinib caused by the C481 mutation of BTK. Here, BTK is linked to diffuse large B-cell lymphoma.